Skip to content
DataLookout
Menu

MR-146NCT07923045

A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Study sites: 11 to 12
    • Study title shortened, about 19 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Dose-Limiting Toxicities (Safety)
Timeframe: Week 52
Incidence of serious adverse events (Safety)
Timeframe: Week 52
Incidence of adverse events (Safety)
Timeframe: Week 52

Arms and interventions

MR-146 (Low)Experimental

Participants will receive a single low dose of MR-146 administered via an intralacrimal gland injection

MR-146 (mid)Experimental

participants will receive a single mid-level dose of MR-146 administered via an intralacrimal gland injection

MR-146 (high)Experimental

participants will receive a single high dose of MR-146 administered via an intralacrimal gland injection

Genetic: MR-146

Sites

12 sites in 1 country